PTO/SB/08B (10-07)

Approved for use through 10/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number						
Substitute for form 1449/PTO	Complete if Known					
	Application Number	10/551,869				
INFORMATION DISCLOSURE	Filing Date	October 31, 2006				
STATEMENT BY APPLICANT	First Named Inventor	Ask Püschl				
(Use as many sheets as necessary)	Art Unit	1625				
(see as many shoots as necessary)	Examiner Name	Not Yet Assigned				
Sheet 3 of 3	Attorney Docket Number	433-US-PCT				

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	U	Sato, T., et al. "Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics". Naunyn-Schmiedeberg's Arch Pharmacol. 2000. 361:214-220.	
	v	Siemsen, P., et al. "Acetylenic Coupling: A Powerful Tool in Molecular Construction". Angew. Chem. Int. Ed. 2000. 39:2632-2657.	
	w	Silverman, R.B. The Organic Chemistry of Drug Design and Drug Action. 1992. San Diego. Academic Press. P.19.	
	x	Tamiz, A.P., et al. "Further SAR Studies of Piperidine-Based Analogues of Cocaine. 2. Potent Dopamine and Serotonin Reuptake Inhibitors". J. Med. Chem. 2000. 43(6):1215-1222.	
	Υ	Wang, S., et al. "Discovery of a Novel Dopamine" Transporter Inhibitor, 41-tydroxy-1-mattly-4.(4-methylphemyl)-3-piperigit 4-Methylphemyl Notrone as a Potential Cocate Amaponie through 3D Database Pharmacophor Searching, Moscular Modeling, Structure - Activity Relationships, and Behavioral Pharmacological Studies". J. Med. Chem. 2000, 43(3): 351-380.	

Examiner Signature		Date Considered	
SEVAMINED: Initial if reference considered, whether exact citation is in conformance with MDED 600. Drow line through citation if not in conformance and not			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is powered by 53 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to late 2 hours of the properties, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information (U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.